BS_BSV07M7Z
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- os_event
- false
- age_years
- 4.603
- sex
- M
- race
- White
- new_clusters
- C6
- umap1_2d
- 3.781756166
- umap2_2d
- 6.443867171
- umap1_3d
- 2.544146829
- umap2_3d
- -0.760826007
- umap3_3d
- -4.844680402
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- DNA_REPAIR+0.480
- OXIDATIVE_PHOSPHORYLATION+0.440
- E2F_TARGETS+0.380
- MYC_TARGETS_V1+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- G2M_CHECKPOINT+0.290
- PI3K_AKT_MTOR_SIGNALING+0.240
- HEDGEHOG_SIGNALING+0.220
- ADIPOGENESIS+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.190
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- TNFA_SIGNALING_VIA_NFKB-0.380
- IL6_JAK_STAT3_SIGNALING-0.360
- KRAS_SIGNALING_UP-0.360
- INTERFERON_GAMMA_RESPONSE-0.350
- ALLOGRAFT_REJECTION-0.330
- IL2_STAT5_SIGNALING-0.310
- COMPLEMENT-0.280
- INTERFERON_ALPHA_RESPONSE-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0553 | Med | Medulloblastoma | 0.901 |
| 2 | MDT-AP-0357 | Med | Medulloblastoma | 0.892 |
| 3 | MDT-AP-2388 | Med | Medulloblastoma | 0.870 |
| 4 | EPT0810 | EPN | Posterior Fossa EPN | 0.864 |
| 5 | MDT-AP-1366 | Med | Medulloblastoma | 0.862 |
| 6 | 1C94EA93-563D-4F65-B857-85EF91127874 | — | — | 0.861 |
| 7 | ERR2208894 | — | — | 0.857 |
| 8 | TCGA-85-8070-01A-11R-2247-07 | — | cohortSQ2 | 0.856 |
| 9 | MDT-AP-0439 | Med | Medulloblastoma | 0.855 |
| 10 | MDT-AP-1214 | Med | Medulloblastoma | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| DNA_REPAIR | 0.480 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.060 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |